BIRC5 expression after drug treatment. (A) Graph comparing the relative expression of BIRC5 in ATL2 and ATL3 before and after (−, +) Zenapax (humanized anti–IL-2Rα) treatment. (B) Expression of BIRC5 in PBLs in lymphoma (ATL8), acute stage (ATL8a), and 3 and 72 hours (ATL8b and 8c) after bortezomib treatment (1.3 mg/m² twice weekly for 2 weeks). (C) The level of expression of antiapoptotic proteins BIRC5 (Abcam), XIAP (Cell Signaling Technology, Danvers, MA), and Bcl-xL (Cell Signaling Technology) were examined by Western blot analysis in whole-cell extracts (50 μg) from ATL patient 8. Actin levels were determined as a loading control. Also shown are the levels of IκBα (EMD Chemicals, Gibbstown, NJ). (D) Total RNA from untreated (−) or treated (+) cells with 10 nM bortezomib was analyzed on Apoptosis GEarrays (Superarray Bioscience). BIRC5 expression in untreated samples was set at 1.